Arbutus Biopharma

Arbutus Biopharma Corp. is a biopharmaceutical company. It engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arbutus Biopharma advances promising drug candidates and secures financial stability

Arbutus Biopharma showcased progress in its drug development pipeline, particularly with positive Phase IIa trial results for AB-729 and the introduction of AB-343 as a promising oral coronavirus drug candidate. The company's financial stability and strategic focus on upcoming milestones position it well for future growth.

Arbutus Biopharma advances HBV and COVID-19 treatments with strong finances

Arbutus Biopharma is making significant progress in developing treatments for HBV and COVID-19, supported by a strong financial position.
While facing challenges such as FDA clinical holds and trial planning, the company is well-positioned to capitalize on upcoming opportunities.
Strategic focus on clinical advancements, financial stability, and future growth opportunities defines Arbutus Biopharma's outlook for 2023.

Arbutus Biopharma advances Hepatitis B cure development amid financial strength

Arbutus Biopharma is progressing well in its quest for a functional cure for chronic Hepatitis B, supported by a strong pipeline and financial stability.
The company faces challenges in navigating development hurdles and competition but has opportunities to lead in innovative therapies for HBV and COVID-19.
By focusing on key milestones, strategic trial designs, and effective resource management, Arbutus aims to drive growth and success in the biopharmaceutical sector.

Arbutus Biopharma focuses on HBV cure amid leadership transition

Arbutus Biopharma's strategic focus on developing a functional cure for chronic HBV and maintaining financial stability through 2026 positions the company for future growth.
While workforce reduction and legal challenges present hurdles, the company's pipeline progress and leadership transition signal resilience and adaptability.
Opportunities in pipeline expansion, partnerships, and clinical trial advancements underscore Arbutus Biopharma's potential for long-term success in the biopharmaceutical industry.

Arbutus Biopharma focuses on HBV cure, extends cash runway

Arbutus Biopharma's Q4 2023 earnings call highlighted a strategic focus on HBV and extending cash runway. Progress in clinical trials and ongoing litigation efforts against key players. Anticipating reduced cash burn in 2024 for financial sustainability.

Arbutus Biopharma reports strong financials and progresses HBV treatment pipeline

Arbutus Biopharma showcased a strong financial position and positive results in Phase 1a study of AB-836.
The company's focus on developing a functional cure for chronic HBV and advancing pipeline assets demonstrates commitment to innovation.
While facing questions on dosing strategies and trial designs, Arbutus sees opportunities in upcoming data releases and advancing clinical studies.

Arbutus Biopharma reports promising HBV trial results and financial strength

Arbutus Biopharma demonstrates positive trial results and financial stability, positioning the company well for future growth and innovation in HBV treatment
Challenges in trial design, data interpretation, and legal proceedings require careful navigation to capitalize on opportunities for advancement
Opportunities lie in further data reporting, biomarker exploration, and potential partnerships to drive progress towards a functional cure for chronic hepatitis B

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

﻿Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks

Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement

Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.

Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options

Moderna

The patents subject to the court's ruling cover a lipid formulation for nucleic acid delivery, which is essential for Moderna's COVID-19 vaccines.

Moderna drops, Arbutus pops after patent ruling means vaccine maker could owe royalties on billions in COVID shot revenue

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 50% during intraday trading today. This is why it happened.

Arbutus Biopharma (ABUS) Stock: Why The Price Is Surging Today

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core protein, which in turn is required for viral replication. Arbutus shares are soaring after the Patent Trial and Appeals Board has turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on the COVID-19 Vaccine Delivery Technology Patent.

Arbutus' Hepatitis B Candidate Shows Encouraging Antiviral Activity

Arbutus Biopharma (ABUS) stock is taking off on Wednesday thanks to a court ruling in its favor in a case against Moderna (MRNA). The post ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today appeared first on InvestorPlace.

ABUS Stock Alert: The Moderna News That Has Arbutus Biopharma Shares Rocketing Today

Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-delivery technology. A federal appeals court upheld the ruling to not invalidate patents held by Arbutus.

Why Arbutus Shares Are Soaring Today

A recent court of appeals decision is bad news for Moderna and great news for Arbutus Biopharma.

Why Arbutus Biopharma Is Rocketing Higher Today

WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (cHBV) infection and to treat coronaviruses (including COVID-19), today announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next generation capsid inhibitor, AB-836, is generally safe and well-tolerated in both healthy subjects and patients with cHBV and provides robust antiviral activity.

Preliminary Data Shows that Arbutus' Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity

Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals Board has turned down Moderna, Inc.'s (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-delivery technology used in the former's COVID-19 vaccine.

Arbutus Shares Are Soaring As Moderna Loses Appeal Of Board Ruling On COVID-19 Vaccine Delivery Technology Patent

Recent Acquisition of RNAi drug maker Dicerna by Novo Nordisk makes a case for eventual partnership/buyout of Arbutus Biopharma. AB-729 has proven to work in treating patients with Hepatitis B with significant Hepatitis B surface antigen reduction alone. Four triple combinations studies have started or will be initiated soon.

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

WARMINSTER, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that Tram Tran, M.D. has been appointed to the Arbutus Board of Directors effective immediately. Dr. Tran is a renowned liver and viral specialist with over 20 years of academic and industry experience as a physician scientist.

Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors

Arbutus' Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B

Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®

WARMINSTER, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different modes of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the Jefferies London Healthcare Conference.

Arbutus to Participate at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call Transcript

Arbutus (ABUS) delivered earnings and revenue surprises of 0.00% and 41.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates

On-track for multiple data readouts of AB-729 and AB-836 in Q4 2021

Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update

WARMINSTER, Pa., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that the Company will be presenting data on the effects of its GalNAc-siRNA, AB-729, in chronic hepatitis B patients on nucleos(t)ide analogue therapy at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting ® 2021 – The Digital Experience™, taking place from November 12-15, 2021.

Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know

Alpine 4 Holdings

Digital Brands Group Inc

Progenity

Waitr Holdings Inc

Are these penny stocks ready to short squeeze? The post 5 Short Squeeze Penny Stocks To Watch For November 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Short Squeeze Penny Stocks To Watch For November 2021

WARMINSTER, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of wholly-owned assets with different mechanisms of action to provide a cure for people with chronic hepatitis B virus (HBV) infection and to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2021 financial results and corporate update for Thursday, November 4, 2021. The schedule for the press release and conference call/webcast are as follows:

Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update

Aditxt Inc

Adverum Biotechnologies

Ameri Holdings

Evofem Biosciences Inc

Are these 10 penny stocks on your watch list this week? The post Best Penny Stocks To Buy This Week?

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

Kaleido Biosciences Inc

MannKind

Trevena

Will upcoming events mean big things for these penny stocks? The post 5 Penny Stocks To Watch This Week With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch This Week With Potential Biotech Catalysts

WARMINSTER, Penn., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in the following October investor conferences:

News for Arbutus Biopharma Stock (ABUS)